- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Patient Journey: Effectively Managing AD Itch Early On
The panel delves into the most challenging symptoms of atopic dermatitis (AD), maps out the patient journey, and highlights crucial factors in effectively managing itch and other AD-related symptoms.
EP: 1.Tackling Key Concerns in Atopic Dermatitis + Biologic Use
EP: 2.Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape
EP: 3.Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment
EP: 4.Experts Discuss Long-Term Effects and Monitoring in AD Therapy
EP: 5.Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD
EP: 6.The Patient Journey: Effectively Managing AD Itch Early On
EP: 7.Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies
EP: 8.Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care
- What are some of the most burdensome symptoms of AD that patients commonly experience, and how do these symptoms impact their quality of life?
- How do you prioritize treating itch in adult patients with atopic dermatitis (AD), and what strategies have you found most effective in managing this symptom promptly?
- Share your experience regarding time to resolution of itch with ruxolitinib topical therapy compared to other treatment options.
- When considering formulary decisions, how is the time-to-disease-control incorporated into these decisions?
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
